Davis Polk the initial purchasers in connection with a Rule 144A offering by Cantel Medical Corp. of $140 million principal amount of 3.250% convertible senior notes due 2025. Cantel’s common stock is listed on the NYSE under the symbol “CMD.”
Cantel, headquartered in New Jersey, is a leading provider of infection prevention products and services in the healthcare market, including specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, instruments and instrument reprocessing workflow systems serving the dental industry, dialysate concentrates, hollow fiber membrane filtration and separation products.
The Davis Polk capital markets team included partner Richard D. Truesdell Jr., associates Andrew J. Terjesen and Michael F. Power. The equity derivatives team included partner Mark J. DiFiore and associates Crystal Chi and Danielle Forni. The tax team included counsel Ethan R. Goldman. Counsel Bonnie Chen and associate Daniel P. Kearney provided intellectual property advice. Counsel David A. Zilberberg provided environmental advice. All members of the Davis Polk team are based in the New York office.